Myriad Genetics agreed to pay former Chief Commercial Officer Brian Donnelly $1.3 million and make some share awards his sooner. These added costs weigh against the company, though his departure was already disclosed.
The cash payment and earlier share awards create costs without any stated business gain. Donnelly had already left, and the payment follows his existing severance agreement, so this filing adds details to a departure already known.
Follow Myriad Genetics, Inc. (MYGN) free. When we publish a story about it, you get the plain-English explanation as an alert.
Get alerts for MYGN